Vilar J B, Leite K R, Chen Chen L
Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brazil.
Genet Mol Res. 2009 Mar 24;8(1):328-33. doi: 10.4238/vol8-1gmr519.
Ginkgo biloba (Egb 761) extract, the most prescribed phytomedicine in Europe for the treatment of cerebral insufficiency and vascular diseases, was tested for its possible protective effects against mitomycin C (MMC)- and cyclophosphamide (CP)-induced mutagenicity using the micronucleus test in mouse bone marrow. The extract was co-administered to mice at doses of 50, 100 and 200 mg/kg (po) with 4 mg/kg (ip) MMC or 24 mg/kg (ip) CP. All doses of Egb 761 were significantly (P < 0.05) effective in reducing the frequency of micronucleated polychromatic erythrocytes, when compared with MMC or CP alone. Based on these results, we suggest that Egb 761 possesses both direct and indirect antimutagenic potential.
银杏叶提取物（Egb 761）是欧洲治疗脑供血不足和血管疾病最常用的植物药，本研究采用小鼠骨髓微核试验检测其对丝裂霉素C（MMC）和环磷酰胺（CP）诱导的致突变性的可能保护作用。将提取物以50、100和200mg/kg（口服）的剂量与4mg/kg（腹腔注射）MMC或24mg/kg（腹腔注射）CP共同给予小鼠。与单独使用MMC或CP相比，所有剂量的Egb 761均能显著（P<0.05）降低微核多染红细胞的频率。基于这些结果，我们认为Egb 761具有直接和间接的抗诱变潜力。
